Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-Current Assets (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Non-Current Assets for 4 consecutive years, with $30.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 65.95% to $30.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $123.3 million, a 98.35% increase, with the full-year FY2025 number at $30.2 million, up 65.95% from a year prior.
  • Non-Current Assets was $30.2 million for Q4 2025 at Phathom Pharmaceuticals, down from $32.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $32.5 million in Q3 2025 to a low of $3.3 million in Q1 2022.
  • A 4-year average of $15.0 million and a median of $13.9 million in 2024 define the central range for Non-Current Assets.
  • Biggest YoY gain for Non-Current Assets was 288.41% in 2024; the steepest drop was 10.81% in 2024.
  • Phathom Pharmaceuticals' Non-Current Assets stood at $4.3 million in 2022, then soared by 281.81% to $16.4 million in 2023, then grew by 10.81% to $18.2 million in 2024, then skyrocketed by 65.95% to $30.2 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Non-Current Assets are $30.2 million (Q4 2025), $32.5 million (Q3 2025), and $31.3 million (Q2 2025).